↓ Skip to main content

Corticosteroids or ACTH for acute exacerbations in multiple sclerosis

Overview of attention for article published in Cochrane database of systematic reviews, October 2000
Altmetric Badge

Citations

dimensions_citation
136 Dimensions

Readers on

mendeley
133 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Corticosteroids or ACTH for acute exacerbations in multiple sclerosis
Published in
Cochrane database of systematic reviews, October 2000
DOI 10.1002/14651858.cd001331
Pubmed ID
Authors

Antonietta Citterio, Loredana La Mantia, Gabriele Ciucci, Livia Candelise, Fabio Brusaferri, Rune Midgard, Graziella Filippini

Abstract

Corticosteroids are often used to improve the rate of recovery from acute exacerbation in multiple sclerosis (MS) patients. However, it is still unclear just how relatively effective these agents are and the type of drug, optimal dose, frequency, duration of treatment and route of administration are unknown. The object of this review was to determine the efficacy and safety of corticosteroids or ACTH in reducing the short and long term morbidity from MS. Moreover, we wished to examine from indirect comparisons if the effect of corticosteroids is different according to different doses and drugs, routes of administration, length of treatment. A search strategy developed for the Cochrane MS Group (last searched: June 1999) completed with handsearching and personal contacts with trialists and pharmaceutical companies was used. All randomised, double-blind, unconfounded trials comparing corticosteroids or ACTH to placebo in patients with MS, treated for acute exacerbations, without any age or severity restrictions, were evaluated. Two reviewers independently selected articles for inclusion, assessed trials' quality and extracted the data. A third reviewer cross-checked them and disagreements were resolved by a joint discussion. Six trials contributed to this review; a total of 377 participants (199 treatment, 178 placebo) were randomised. The drugs analysed were methylprednisolone (MP) (four trials, 140 patients) and ACTH (two trials, 237 patients). Overall, MP or ACTH showed a protective effect against the disease getting worse or stable within the first five weeks of treatment (odds ratio[OR]=0.37, 95% confidence interval [CI] 0.24-0.57) with some but non significant greater effect for MP and intravenous administration. Short (five days) or long (15 days) duration of treatment with MP did not show any significant difference. Only one study (with 51 patients) reported data after one year of follow-up: no difference between oral MP and placebo in the prevention of new exacerbations or improvement in long term disability was detected. No data are available beyond one year of follow-up to indicate whether steroids or ACTH have any effect on long-term progression. One study reported that a short term treatment with high dose intravenous MP was not attended by adverse events. On the contrary, gastrointestinal symptoms and psychic disorders were significantly more common in the oral, high-dose MP than in the placebo group. Weight gain and edema were significantly more frequent in the ACTH group than in controls. We found evidence favouring the corticosteroid MP for acute exacerbation in MS patients. Data are insufficient to reliably estimate effect of corticosteroids on prevention of new exacerbations and reduction of long-term disability. Studies assessing long term risk/benefit and adverse effects of corticosteroids in MS patients are urgently needed.

Mendeley readers

The data shown below were compiled from readership statistics for 133 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 2%
Spain 2 2%
United Kingdom 1 <1%
Japan 1 <1%
Germany 1 <1%
Ecuador 1 <1%
Unknown 124 93%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 23 17%
Researcher 22 17%
Student > Master 17 13%
Student > Bachelor 14 11%
Other 13 10%
Other 44 33%
Readers by discipline Count As %
Medicine and Dentistry 60 45%
Unspecified 19 14%
Agricultural and Biological Sciences 10 8%
Neuroscience 10 8%
Psychology 8 6%
Other 26 20%